1 Citazione (Scopus)

Abstract

Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone layer have been developed for the treatment of AR. The use of these devices might improve patients' adherence to treatment, avoiding some of the most common side effects associated with aqueous formulations. This review provides the most recent evidence for the efficacy and safety of beclomethasone dipropionate hydrofluoroalkane nasal aerosol in the treatment of allergic rhinitis.
Lingua originaleEnglish
pagine (da-a)1-10-10
Numero di pagine10
RivistaExpert Review of Clinical Immunology
Stato di pubblicazionePublished - 2015

Fingerprint

HFA 134a
Beclomethasone
Adrenal Cortex Hormones
Stratospheric Ozone
Nasal Sprays
Therapeutics
Patient Compliance
Quality of Life
Guidelines
Psychology
Safety
Equipment and Supplies
Allergic Rhinitis

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology

Cita questo

Beclomethasone dipropionate hydrofluoroalkane for the treatment of allergic rhinitis. / Cilluffo, Giovanna; Ferrante, Giuliana; Malizia, Velia; Marchese, Donatella; Montalbano, Laura; La Grutta, Stefania; Malizia, Velia; Marchese, Donatella; Montalbano, Laura; Cilluffo, Giovanna.

In: Expert Review of Clinical Immunology, 2015, pag. 1-10-10.

Risultato della ricerca: Article

@article{5343bfc84a99438f9c0dcba1f436d4fb,
title = "Beclomethasone dipropionate hydrofluoroalkane for the treatment of allergic rhinitis",
abstract = "Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone layer have been developed for the treatment of AR. The use of these devices might improve patients' adherence to treatment, avoiding some of the most common side effects associated with aqueous formulations. This review provides the most recent evidence for the efficacy and safety of beclomethasone dipropionate hydrofluoroalkane nasal aerosol in the treatment of allergic rhinitis.",
author = "Giovanna Cilluffo and Giuliana Ferrante and Velia Malizia and Donatella Marchese and Laura Montalbano and {La Grutta}, Stefania and Velia Malizia and Donatella Marchese and Laura Montalbano and Giovanna Cilluffo",
year = "2015",
language = "English",
pages = "1--10--10",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Beclomethasone dipropionate hydrofluoroalkane for the treatment of allergic rhinitis

AU - Cilluffo, Giovanna

AU - Ferrante, Giuliana

AU - Malizia, Velia

AU - Marchese, Donatella

AU - Montalbano, Laura

AU - La Grutta, Stefania

AU - Malizia, Velia

AU - Marchese, Donatella

AU - Montalbano, Laura

AU - Cilluffo, Giovanna

PY - 2015

Y1 - 2015

N2 - Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone layer have been developed for the treatment of AR. The use of these devices might improve patients' adherence to treatment, avoiding some of the most common side effects associated with aqueous formulations. This review provides the most recent evidence for the efficacy and safety of beclomethasone dipropionate hydrofluoroalkane nasal aerosol in the treatment of allergic rhinitis.

AB - Allergic rhinitis (AR) is a common respiratory disease, and its prevalence is increasing all over the world, both in adults and in children. Patients experience symptoms that may negatively impact on physical, social and psychological well-being. Hence, if left untreated, allergic rhinitis may significantly affect quality of life. Under current guidelines, intranasal corticosteroids are considered the most effective drugs and they are recommended as first-line therapy. Among the several corticosteroid intranasal sprays available, beclomethasone dipropionate is one of the most prescribed. Recently, new intranasal hydrofluoroalkane-propelled formulations with little or no impact on the ozone layer have been developed for the treatment of AR. The use of these devices might improve patients' adherence to treatment, avoiding some of the most common side effects associated with aqueous formulations. This review provides the most recent evidence for the efficacy and safety of beclomethasone dipropionate hydrofluoroalkane nasal aerosol in the treatment of allergic rhinitis.

UR - http://hdl.handle.net/10447/172006

UR - http://www.tandfonline.com/doi/full/10.1586/1744666X.2016.1118347.

M3 - Article

SP - 1-10-10

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

ER -